As the different genetic backgrounds of our tumour (DoHH-2) and non-tumour (GM01953) cell lines could contribute to the observed differences in eIF4B interactomes, direct comparisons should be made cautiously; however, these data do suggest that eIF4B is required for the efficient regulation of histone mRNAs to drive S-phase progression and provide further rationale for targeting high levels of eIF4B in DLBCL and other malignant diseases. Here, EIF4B is linked to diffuse large B-cell lymphoma.